Use of hipsc derived Cardiomyocytes for Cardiac Safety Evaluation
|
|
- Kristina Parks
- 5 years ago
- Views:
Transcription
1 Use of hipsc derived Cardiomyocytes for Cardiac Safety Evaluation Liang Gu, MD, Msc Sr. Principal Scientist/Lab Head, ADRD Investigative Toxicology March 14 th, 2018 (SOT Workshop) DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute Frederick National Laboratory is a Federally Funded Research and Development Center operated by Leidos Biomedical Research, Inc., for the National Cancer Institute
2 Disclaimer The speaker is an employee of Leidos Biomedical Research, Inc. (LBRI), a government contractor to operate Frederick National Laboratory for Cancer Research (FNLCR) in support of NIH/NIC initiatives No conflicts of interest to disclose
3 Outlines Definition of cardiotoxicity: functional vs. structural Use of human induced pluripotent stem cell derived cardiomyocytes (hipsc CMs): In CiPA initiative as a translational model As high/moderate throughput assays to screen for both types of cardiotoxicity Cellular impedance (+ biochemical/high content analysis) Ca 2+ transit (+ biochemical/high content analysis) In mechanistic studies to investigate on target cardiotoxicity of trastuzumab (Herceptin ) Model potentiation of ErbB2 inhibition on anthracycline cardiotoxicity Take home messages
4 Pathophysiological classification of cardiotoxicity Cardiotoxicity: toxicity that affects the heart Pathology (myocardial destruction) Physiology (arrhythmia and/or contractility ) Onset/progression rate Functional Structural Mixed ( ) (+) (+) (+) primary fast, instantaneous/acute (minutes to hours) (+) secondary delayed onset, slow, subacute/chronic (days to years) (+) primary & secondary both Reversibility yes no yes/no Mechanism(s) ion channels and/or receptors key components in cell death/survival pathways both Therapeutic area(s) dofetilide, sotalol, terfenadine, nilotinib anthracycline, trastuzumab sunitinib, dasatinib National Cancer Institute NIH. NCI Dictionary of Cancer Terms <
5 hipsc CMs as a translational model Cell based in vitro models for screening and mechanistic study in drug development: Pros: Human origin eliminate concerns on species discrepancy Functional with spontaneous beating enable comprehensive test Easy for long term (> 3 months) culture enable test on chronic effects Easy to create CMs with specific genotype model diseases Cons: Fetal like phenotype impact on drug responses!!! Mixture of nodal, atrial and ventricular cells difficult to identify target cell type Fit-for-purpose validation of endpoints is critical for translatability!
6 Endpoint selection for quantitative functional and structural testing in hipsc CMs Functional Electrophysiology: Action potential (AP) Field potential (FP) Ca 2+ cycling: [Ca 2+ ]i Force generation Transducer Cell length Movement Excitation Contraction Coupling Bers 2002 Nature Structural Cellular morphology Membrane permeabilization LDH, ctni release Nuclear stain Apoptosis and cell loss Caspase 3/7, ATP Nucleus count Mitochondrial damage Mito membrane potential (JC 10 stain)
7 Update on hipsc CMs as a key component in CiPA initiative Comprehensive in Vitro Proarrhythmia Assay (CiPA) ICH S7B and E14 guidelines: herg inhibition and QT prolongation as a surrogate CiPA goal: focus on proarrhythmic propensity with arrhythmia like events as a predictor Four components: Work on myocytes: 34 sites participated 28 compounds tested 2 platforms (MEA/VSD) evaluated 2 manuscripts submitted MEA VSD These results demonstrate the utility of hipsc-cms to detect drug-induced proarrhythmic effects
8 Cellular impedance platform as a screening tool Workflow Real-time Non-invasive Dosing Biochemical, imaging Cardiac myocytes 96-well E-plate Cardio xcelligence RTCA Cardio Technology Contraction Relaxation Readout Electrical impedance Viability (CI) Contraction ( CI), Rhythm Biochemical measurement Caspase 3/7, ATP, LDH, ctni High-content analysis (optical plates) Total/dead cell count MMP (JC-10 stain)
9 Validation of Cellular Impedance as a functional endpoint Impedance vs. Field Potentials: A Arrhythmic beats Regular beat Signals match with each other Field potential Impedance Impedance, not Field Potential, suppressed by a myosin ATPase inhibitor Blebbistatin B Baseline Na + Spike Impedance 1 μm Blebbistatin Na + Spike Impedance Impedance waveforms represent contraction of cardiomyocytes! Field potential Field potential Guo et al, 2015 CPiCB
10 Validation of impedance to predict functional and structural cardiotoxicity E 4031 (functional) A B 0.03 M 30 hrs 30 min 72 hrs Sunitinib (mixed) A B 30 hrs 30 min 3 M 72 hrs Guo et al, 2013, Tox Sci 30 min 30 hrs 30 min 30 hrs ( M) Doxorubicin (structural) A B ( M) 0 30 min hrs 1 M 72 hrs Parameters: 30 min 30 hrs Irregular Beat (IB) ratio = irregular/total beats to predict proarrhythmic risk Beat Rate (BR) reduction = % in beat rate corrected by the time matched vehicle control to predict QT prolongation liability ( M)
11 Validation of model performance to predict proarrhythmic liability Receiver operating characteristic (ROC) on ~120 compounds A Arrhythmia prediction > 80% B QT prediction > 80% Parameters to predict 1. Arrhythmia: IB 20 : threshold conc. to induce 20% arrhythmic beats PPS IB 20 : IB 20 /Cmax 2. QT prolongation: BR 20 : threshold conc. to induce reduction in beat rate by 20% PPS BR 20 : BR 20 /Cmax C Specificity (%) 1 Specificity (%) 3x Cmax D BR20 PPS-BR20 20 herg (+) 90 BR20 80 PPS-BR20 70 herg (+) x Cmax Guo et al, 2013, Tox Sci. 40 IB (μm) BR (μm) PPS IB x10 3 PPS BR x 10 3
12 Impedance and ATP predict structural cardiotoxicity Validation with 40 compounds: Sequential measurement of Impedance & ATP at 72 hrs drug exposure Cellular Impedance ATP In vitro-in vivo concordance Impedance 10x Sensitivity Specificity IV IV correlation ATP Sensitivity Specificity IV IV correlation Ratio of IC 50 /Cmax Ratio of IC50/Cmax Doxorubicin(+) Carfilzomib(+) Epirubicin(+) Vemurafenib Mitoxantrone(+) Sorafenib(+) Idarubicin(+) Cisplatin(+) Bortezomib(+) Imatinib(+) Paclitaxel(+) Dasatinib(+) Nilotinib(+) Vorinostat Lapatinib(+) Ixabepilone(+) Moxifloxacin Pirarubicin(+) Eribulin Erlotinib Temsirolimus Sunitinib(+) Dobutamine Pioglitazone 5 Fluorouracil(+) Dexrazoxane Ceftazidime 4 acetamidophenol Amoxicillin Sotalol Captopril Cavedilol Levosimendan Gefitinib Atenolol Thalidomide Vincristine Propranolol Benzthiazide Salbutamol Positive hits (%) Parameter: Ratio of IC 50 /Cmax Impedance model is the first line assay to test for cardiac liability 10x
13 Ca 2+ transit platform as a screening tool Functional Structural Cells plated Replated Assays for Ca 2+ transit DNA stain, ATP, Caspase 3/7, JC10, etc. 1 week 1 week 30 min 72 hrs Load Cal-520 Imaging-dose-imaging Temperature & CO 2 control DNA dye JC-10 live-stain IN-Cell Analyzer (HCA) 6-well plate 384-well optic plate Caspase 3/7 ATP Nikon Eclipse Ti Fluorescence Microscope Tecan plate reader
14 Imaging Ca2+ transits 1x objective lens Sampling at 51 fps 1000 FU A Ca2+ transient trace taken from one well at 1x: 20x objective lens 5s hipsc-cms from Stanford Cardiovascular Institute (SCVI) Biobank (Dr. Joseph Wu) Frederick National Laboratory for Cancer Research
15 Multi parameter analysis with CYBERnano i Cardio software: Ca 2+ transit duration (CTD) as a surrogate of action potentiation duration (APD) Cal 520 intensity (RU) [Ca 2+ ] amplitude CTD30 CTD90 Inter-Peak Interval [Ca 2+ ] baseline Time (s) Beat rate: number of Ca 2+ transit peaks/minute [Ca 2+ ] baseline: Cal 520 intensity prior to a transit [Ca 2+ ] amplitude: Cal 520 intensity between baseline and peak Peak-Peak Interval (PPI): time between two transit peaks [Ca 2+ ] rising rate (RR): the rate of Cal 520 intensity rising from 10 to 70% of peak [Ca 2+ ] falling rate (FR): the rate of Cal 520 intensity falling from 70 to 10% of peak Inter-Peak Interval (IPI): time between two transit peaks Ca 2+ transit duration 30 (CTD30): duration at 30% level from peak Ca 2+ transit duration 90 (CTD90): duration at 10% level from peak Corrected CTD30: corrected by beat rate = CTD30(n)/IPI(n-1) Corrected CTD90: corrected by beat rate = CTD90(n)/IPI(n-1) Triangulation index: = CTD90c/CTD30c or Beat-to-beat variability
16 Ca 2+ transit predicts proarrhythmic liability Representative responses to herg inhibition at 30 min post dose Pre-dose CTD prolongation + beat rate EAD CTD prolongation + EADs Tachycardia Fibrillation Beat arrest CTD, Ca 2+ transit duration; EADs, early-afterdepolarization-like events
17 Nuclear stain detects cell death (membrane permeabilization) Representative responses to structural cardiotoxicant at 72 hours post dose A B C 0.1% DMSO Doxorubicin 3μM 450 Number of cells % DMSO Dox 0.3 μm Dox 1 μm Dox 3 μm DAPI: permeable; DRAQ7:impermeable DAPI/DRAQ7 20 μm DRAQ7 intensity (RFU) Ca 2+ transit model was used to determine MOA and therapeutic index of compounds with anticancer activity but interruption of Ca 2+ cycling
18 Case study: investigation on ErbB2 inhibition mediated on target toxicity The double edged sword of ErbB2 inhibitor Trastuzumab (Herceptin ): The Good ( Survival rate) The Bad ( Heart failure/cardiomyopathy) Anthracycline + Trastuzumab Trastuzumab Anthracycline None or other Years Since Start of Treatment HER2/ErbB2+ breast cancer; Romond EH, et al., N Engl J Med, 2005; 353: Aiello Bowles EJ, et al., J Natl Cancer Inst, 2012; 104: Pre clinical and clinical safety evaluation failed to predict cardiotoxicity at this level of severity! How can we improve strategy to prevent the next trastuzumab?
19 Mechanism of trastuzumab liability: on target toxicity HER2/ErbB2 expressed in Tumor Cell & Cardiomyocytes: HER2/ErbB2(+) Tumor Trastuzumab Myocardia ERK1/2 AKT ERK1/2 AKT ERK1/2 AKT De Keulenaer GW, et al., Circ Res, 2010; 106: ErbB2 agonist: Neuregulin-1β (NRG) Are hipsc CMs capable of modeling cardiotoxicity observed in the clinical?
20 BArea normalized to GAPDH ErbB2 is present and functional in hipsc CMs Expression Knockdown Functional A KDa ErbB KDa ErbB2 C 8.0 WES WES NanoPro pi cardiomyocytes H441 GAPDH GAPDH 5.0 pakt Area normalized to GAPDH cardiomyocytes H441 EGFR ErbB2 ErbB4 ErbB3 ErbB Control sirna 75% ErbB2 sirna Electropherogram pakt 0.01% DMSO 20 ng/ml NRG Lapatinib + NRG Trastuzumab + NRG
21 Model modulation of Doxorubicin (Dox) toxicity by ErbB2 signaling Impedance Functional Biochemical A Dose Dox LDH, ATP 8 hrs 40 hrs NRG Tras NRG+Dox Dox Tras+Dox Time (hrs) B Tras+Dox NRG+Dox Dox Vehicle Pre-dose Post-dose 8 hrs 40 hrs C Absorbance Luminescence x10 6 4x10 6 2x10 6 LDH ATP Mean ± SE (n=3-6 wells); at 1μM (Dox, Trastuzumab) or at 100 ng/ml (NRG);, p < 0.05 compared to vehicle or Dox Eldridge et al., Tox Sci 2014; Guo et al. CPiCB 2015
22 Model modulation of Doxorubicin (Dox) toxicity by ErbB2 signaling Nucleus morphology 0.1% DMSO Dox 1 μm % nucleus area < 50 μm Nucleus size 0.1%DMSO Tras 1μM NRG 100 ng/ml Apoptosis Dox 1μM Tras + Dox 1μM NRG + Dox 1μM Tras + Dox 1 μm 20 μm Guo et al. CPiCB 2015 NRG + Dox 1 μm Luminescence 1,600,000 1,200, , ,000 0 Caspase 3/7 0.1% DMSO Tras 1 um NRG 100 ng/ml Dox 1μM Tras + Dox 1μM NRG + Dox 1μM Mean ± SE (n=3-6 wells); at 1μM (Dox, Trastuzumab) or at 100 ng/ml (NRG);, p < 0.05 compared to vehicle or Dox
23 Take home message: hipsc-cms are a useful translational in vitro model system for cardiac safety evaluation Multiple platforms are available for assessing both functional and structural cardiotoxicity using screening and mechanistic approaches Fit-for-purpose qualification of model system is critical for translatability As demonstrated by our work with ErbB2 inhibitor trastuzumab, hipsc-cms can be a valuable model in chemotherapeutic development to assess on-target cardiac liability, since many of new anticancer targets play an important role in maintaining myocardial survival and functional integrity
24 Acknowledgements: NIH/NCI Roche Nutley Univ. Stanford Univ. Lorraine FNLCR/LBR Sandy Eldridge Myrtle Davis Jerry Collins Luke Coyle Rory Abrams Ray Kemper Eric Chiao Yan Zhuge Joseph C. Wu Levy Bastista Thierry Bastogne Mike Furniss Jodie Mussio John Hamre Ralph Parchment Kyle Kolaja Disclaimers: This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract HHSN E. The content of this presentation does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.
25 Thank you!
Metrion Biosciences: the ion channel specialists
Metrion Biosciences: the ion channel specialists In depth profiling of human ipsc cardiomyocytes: From electrophysiology to phenotypic assays Saïd El-Haou, PhD 30 November 2017 www.metrionbiosciences.com
More informationAssessment of pro-arrhythmic effects using Pluricyte Cardiomyocytes. on the ACEA xcelligence RTCA CardioECR
Assessment of pro-arrhythmic effects using Pluricyte Cardiomyocytes on the ACEA xcelligence RTCA CardioECR Application Note Version 2.1 / March 2018 Contents 1. Introduction 1 2. Assessment of pro-arrhythmic
More informationPerspectives on Evaluating and Managing Cardiovascular Safety Risk for Anticancer Drugs
Perspectives on Evaluating and Managing Cardiovascular Safety Risk for Anticancer Drugs DCTD/DTP/TPB Myrtle Davis, DVM, Ph.D. Chief, Toxicology and Pharmacology Branch Division of Cancer Treatment and
More informationxcelligence RTCA Cardio Instrument Monitor Cardiomyocyte Beating in Real Time for Drug Discovery Research
xcelligence RTCA Cardio Instrument Monitor Cardiomyocyte Beating in Real Time for Drug Discovery Research xcelligence RTCA Cardio Instrument A new way to test for compound cardiotoxicity Cardiac liability
More informationCardiomyocyte? March 14 th 2013
What Makes a Cardiomyocyte a Cardiomyocyte? Kyle Kolaja March 14 th 2013 What Makes a Cardiomyocyte a Cardiomyocyte? Shouldn t proliferate Should beat Should be fairly pure Should look like and express
More informationMultiparametric assessment of the effects of chemotherapeutic drugs on the (electro)physiology of Pluricyte Cardiomyocytes
Multiparametric assessment of the effects of chemotherapeutic drugs on the (electro)physiology of Pluricyte Cardiomyocytes Event Presenter Date Ncardia Workshop Tessa de Korte, MSc December 1, 2017 Page
More informationEffects of reference compounds on impedance signals from stem cellderived human cardiomyocytes
Effects of reference compounds on impedance signals from stem cellderived human cardiomyocytes Herbert M. Himmel, Safety Pharmacology, Bayer Pharma AG, Wuppertal, Germany SPS Webinar Cardiac Safety Testing
More informationAdvances in Safety Pharmacology: Utilizing ipsc-derived cardiomyocytes in early stage safety pharmacology investigations. Blake Anson, PhD.
Advances in Safety Pharmacology: Utilizing ipsc-derived cardiomyocytes in early stage safety pharmacology investigations Blake Anson, PhD. Presentation Outline I. Safety Pharmacology and in-vitro models
More informationNcardia. Assessment of pro-arrhythmic effects in Pluricyte Cardiomyocytes. using the Axion BioSystems Maestro TM MEA system
Ncardia Stem cell experts Assessment of pro-arrhythmic effects in Pluricyte Cardiomyocytes using the Axion BioSystems Maestro TM MEA system Application note Version 2.0 Contents 1. Introduction 1 2. Assessment
More informationSuccesses and Evolving Challenges Posed by the Comprehensive In Vitro Proarrhythmia (CiPA) Initiative
Successes and Evolving Challenges Posed by the Comprehensive In Vitro Proarrhythmia (CiPA) Initiative Gary Gintant Dept. Integrative Pharmacology Integrated Sciences and Technology AbbVie For the CiPA
More informationAssessment of pro-arrhythmic effects using Pluricyte Cardiomyocytes on the ACEA xcelligence RTCA CardioECR
Assessment of pro-arrhythmic effects using Pluricyte Cardiomyocytes on the ACEA xcelligence RTCA CardioECR Version 1.2 CONTENTS Getting started... 3 Technical support and training... 3 1. Introduction...
More informationmesc Derived Cardiomyocytes and the RTCA Cardio Instrument - The Perfect Match for Screening Cardiac Effects
mesc Derived Cardiomyocytes and the RTCA Cardio Instrument - The Perfect Match for Screening Cardiac Effects Dr. Kristina Tressat, Axiogenesis AG ELRIG Drug Discovery II 7-8 Sep 2011, Manchester Challange
More informationVasospasm and cardiac ischemia (Type 3 ) Hypertension Hypotension Arrhythmias Miscellaneous ( pericardial inflammation, valvular abnormalities )
Management of Cardiotoxicity due to Systemic Cancer Therapy Left Ventricular Dysfunction Type 1 cardiac dysfunction Type 2 cardiac dysfunction Vasospasm and cardiac ischemia (Type 3 ) Hypertension Hypotension
More informationMeasuring Cardiac Activity:
icell Cardiomyocytes 2 Application Protocol Measuring Cardiac Activity: Impedance Detection with xcelligence RTCA Cardio System Introduction icell Cardiomyocytes 2, human cardiomyocytes derived from induced
More informationInPulse: Development of an ipsc cardiomyocyte (ipsc-cm) platform to assess drug-induced contractility liabilities.
InPulse: Development of an ipsc cardiomyocyte (ipsc-cm) platform to assess drug-induced contractility liabilities. Sponsors: Arun Sridhar, Peter J. Clements, Brian Berridge, Drug induced contractility
More informationIn Vitro Assessment to Replace the Clinical TQT Study: The Comprehensive In Vitro ProArrhythmia Assay (CiPA) Initiative
In Vitro Assessment to Replace the Clinical TQT Study: The Comprehensive In Vitro ProArrhythmia Assay (CiPA) Initiative Gary Gintant, AbbVie for the Comprehensive in Vitro ProArrhythmia Assay Group Hot
More informationhipsc Cardiomyocytes: Validation Study Results
CENTER FOR DEVICES AND RADIOLOGICAL HEALTH OFFICE OF SCIENCE AND ENGINEERING LABORATORIES hipsc Cardiomyocytes: Validation Study Results Ksenia Blinova, PhD US Food and Drug Administration HESI-CSRC CiPA
More informationFocus Application. Compound-Induced Cytotoxicity
xcelligence System Real-Time Cell Analyzer Focus Application Compound-Induced Cytotoxicity Featured Study: Using the Time Resolving Function of the xcelligence System to Optimize Endpoint Viability and
More informationMeasuring Cardiac Activity:
icell Cardiomyocytes 2 Application Protocol Measuring Cardiac Activity: Impedance and Extracellular Field Potential Detection with CardioExcyte 96 System Introduction icell Cardiomyocytes 2, human cardiomyocytes
More informationA New Comprehensive Translational Paradigm Using Human ipsc-derived Cardiomyocytes for Safety Assessment of Drug-Induced Arrhythmias
A New Comprehensive Translational Paradigm Using Human ipsc-derived Cardiomyocytes for Safety Assessment of Drug-Induced Arrhythmias Armando Lagrutta Safety & Exploratory Pharmacology (SEP) Department
More informationMEA assays using human ipsc-derived cardiomyocytes; challenges and opportunities
MEA assays using human ipsc-derived cardiomyocytes; challenges and opportunities Event Presenter Date EMA Workshop 2017 Tessa de Korte, MSc 2017, October 5 Page 1 Ncardia at a glance Foundation Ncardia
More informationAssessment of pro-arrhythmic effects using Pluricyte Cardiomyocytes on the Axion Maestro system
Assessment of pro-arrhythmic effects using Pluricyte Cardiomyocytes on the Axion Maestro system Version 1.0 CONTENTS Getting started... 3 Technical support and training... 3 1. Introduction... 4 2. Workflow...
More informationPreclinical Cardiovascular Safety in Oncology: Do We Need Plumbers, Electricians, or Strength Trainers?
Preclinical Cardiovascular Safety in Oncology: Do We Need Plumbers, Electricians, or Strength Trainers? Gary Gintant, Ph.D. Dept. Integrative Pharmacology Integrated Sciences & Technology, AbbVie CSRC
More informationPlate-Based Assay Methods for the Assessment of Cellular Health
Plate-Based Assay Methods for the Assessment of Cellular Health Andrew L. Niles, Senior Research Scientist 2012, Promega Corporation. Biological Outcomes in Cell Culture Treatment -Small molecule -Bio-molecule
More informationWelcome to the Exhibitor Tutorial presented by
Welcome to the Exhibitor Tutorial presented by February 1, 217 1 Calcium Handling Assays with Human ipsc-derived Cell Types Coby Carlson, Ph.D. 7 February 217 Transformative Potential of ipsc Technology
More informationFocus Application. Compound-Induced Cytotoxicity
xcelligence System Real-Time Cell Analyzer Focus Application Compound-Induced Cytotoxicity For life science research only. Not for use in diagnostic procedures. Featured Study: Using the Time Resolving
More informationCardio-Oncology: Past Present and Future
Cardio-Oncology: Past Present and Future Lakkana Suwannoi PharmD BCPS BCOP Division of Clinical Pharmacy Faculty of Pharmacy Mahidol University Bangkok THAILAND Outline I. Cardiovascular disease & cancer
More informationAntiarrhythmic Drugs
Antiarrhythmic Drugs DR ATIF ALQUBBANY A S S I S T A N T P R O F E S S O R O F M E D I C I N E / C A R D I O L O G Y C O N S U L T A N T C A R D I O L O G Y & I N T E R V E N T I O N A L E P A C H D /
More informationAssessment of pro-arrhythmic effects using Pluricyte Cardiomyocytes. on the ACEA xcelligence RTCA CardioECR
Assessment of pro-arrhythmic effects using Pluricyte Cardiomyocytes on the ACEA xcelligence RTCA CardioECR User Guide Version 3.0 / March 2018 Contents 1. Introduction 2 2. Workflow 3 3. Important recommendations
More informationDiffering responses of human stem cell-derived cardiomyocytes to arrhythmogenic drugs, determined using impedance measurements
Fundamental Toxicological Sciences (Fundam. Toxicol. Sci.) Vol.3, No.2, 47-53, 2016 47 Letter Differing responses of human stem cell-derived cardiomyocytes to arrhythmogenic drugs, determined using impedance
More informationWe ve crossed the Chasm and climbed out of the Trough. Advances and advantages with ipsc-derived cell types in drug discovery.
We ve crossed the Chasm and climbed out of the Trough. Advances and advantages with ipsc-derived cell types in drug discovery. Blake Anson Ph.D. Oct 31, 2014 Technology Hype Cycle The Chasm The Trough
More informationMeasuring Cardiac Activity:
icell Cardiomyocytes Application Protocol Measuring Cardiac Activity: Intracellular Calcium Flux Detection on the FLIPR Tetra System Introduction icell Cardiomyocytes are human cardiomyocytes that recapitulate
More informationDrugs Controlling Myocyte Excitability and Conduction at the AV node Singh and Vaughan-Williams Classification
Drugs Controlling Myocyte Excitability and Conduction at the AV node Singh and Vaughan-Williams Classification Class I Na Channel Blockers Flecainide Propafenone Class III K channel Blockers Dofetilide,
More informationxcelligence System RTCA Cardio Instrument
xcelligence System Application Note No. 15 January 2013 xcelligence System RTCA Cardio Instrument Preclinical Cardiac Safety Assessment using Human ipsc Derived icell TM Cardiomyocytes Introduction Over
More informationBenchmarking In Silico Models and Candidate Metrics for Assessing the Risk of Torsade de Pointes
Benchmarking In Silico Models and Candidate Metrics for Assessing the Risk of Torsade de Pointes Sara Dutta Division of Applied Regulatory Science/OCP/CDER CRSC/HESI/SPS/FDA Meeting December 11, 2014 Silver
More informationThe QT Interval Safety Endpoint for DR- TB trials. Kelly Dooley & Gary Maartens (Disclaimer: I know very little cardiac electrophysiology)
The QT Interval Safety Endpoint for DR- TB trials Kelly Dooley & Gary Maartens (Disclaimer: I know very little cardiac electrophysiology) The ECG tracing Physiology of a cardiac myocyte Flow of ions (Na
More informationDrug-induced cardiotoxicity: screening methods, regulatory context, commercial environment. Beremans Ltd / Insight Pharma Reports April 2008
Drug-induced cardiotoxicity: screening methods, regulatory context, commercial environment. Overview Beremans Ltd / Insight Pharma Reports April 2008 This report identifies and discusses methods, products
More informationCardio-Oncology: New Development New Concepts of ECG Monitoring - Potential Value
February 15 th, 2019 Cardio-Oncology: New Development New Concepts of ECG Monitoring - Potential Value I Savelieva St George s University of London Declaration of Interest Task Force: Reviewer ACC/AHA/ESC
More informationAssessment of pro-arrhythmic effects using Pluricyte Cardiomyocytes on the Axion BioSystems Maestro TM MEA system
Assessment of pro-arrhythmic effects using Pluricyte Cardiomyocytes on the Axion BioSystems Maestro TM MEA system Version 1.2 CONTENTS Getting started... 3 1. Introduction... 4 2. Workflow... 5 Important
More informationRoohi Ismail-Khan, MD, MS
Roohi Ismail-Khan, MD, MS Associate Member Department of Breast Oncology H. Lee Moffitt Cancer Center Associate Professor University of South Florida Department of Oncological Sciences September 27, 2018
More informationJapanese Stem Cell Efforts
Japanese Stem Cell Efforts Yuko Sekino, Ph. D. Organizer of JiCSA Head, Division of Pharmacology, National Institute of Health Sciences (NIHS) Pharmaceutical and Medical Safety Bureau NI HS Since 1874
More informationCardiac toxicity is a leading cause for drug attrition during. Molecular Cardiology
Molecular Cardiology Drug Screening Using a Library of Human Induced Pluripotent Stem Cell Derived Cardiomyocytes Reveals Disease-Specific Patterns of Cardiotoxicity Ping Liang, MD, PhD*; Feng Lan, PhD*;
More informationTdP Mechanisms and CiPA
TdP Mechanisms and CiPA Craig T. January, MD, PhD Division of Cardiovascular Medicine University of Wisconsin-Madison Cardiac Safety Research Consortium Hilton Washington DC December 6, 2016 Disclosures
More informationHESI Technical Committee on Cardiovascular Safety: Advancing the clinical relevance of preclinical assessments
HESI Technical Committee on Cardiovascular Safety: Advancing the clinical relevance of preclinical assessments Brian R. Berridge, DVM, PhD, DACVP Committee Co-Chair ILSI Health and Environmental Sciences
More informationEvolution of strategies to improve preclinical cardiac safety testing
OPINION Evolution of strategies to improve preclinical cardiac safety testing Gary Gintant, Philip T. Sager and Norman Stockbridge Abstract The early and efficient assessment of cardiac safety liabilities
More informationBreakout #4 Phase 1 ECG:
Breakout #4 Phase 1 ECG: Potential Role of ECG under CiPA HESI CSRC CiPA Meeting Washington, DC - May 22, 2018 Jose Vicente, PhD Christine Garnett, PharmD Division of Cardiovascular and Renal Products
More informationDeveloping and Validating an In Silico Model for Proarrhythmia Risk Assessment Under the CiPA Initiative
Developing and Validating an In Silico Model for Proarrhythmia Risk Assessment Under the CiPA Initiative May 2018 Zhihua Li, PhD for the CiPA In Silico Working Group US Food and Drug Administration This
More informationComparison of different proarrhythmia biomarkers in isolated rabbit hearts
Comparison of different proarrhythmia biomarkers in isolated rabbit hearts Summary of PhD Thesis Szabolcs Orosz, MSc Supervisor: Attila Farkas MD, PhD 2nd Dept. of Internal Medicine and Cardiology Centre
More informationSystem. xcelligence System RTCA HT Instrument. Application Note No. 14 /January Long-Term High-Throughput Cytotoxicity Profiling
System Application Note No. 14 /January 2013 xcelligence System RTCA HT Instrument Long-Term High-Throughput Cytotoxicity Profiling For life science research only. Not for use in diagnostic procedures.
More informationRate and Rhythm Control of Atrial Fibrillation
Rate and Rhythm Control of Atrial Fibrillation April 21, 2017 춘계심혈관통합학술대회 Jaemin Shim, MD, PhD Arrhythmia Center Korea University Anam Hospital Treatment of AF Goal Reducing symptoms Preventing complication
More informationCardiac Safety Assessment. In-Vitro/In-Vivo Extrapolation
Cardiac Safety Assessment In-Vitro/In-Vivo Extrapolation Drugs removed from the market for arrhythmia risk Courtesy of Dr. Norman Stockbridge Copyright 2014 Certara, L.P. All rights reserved. 2 Let s have
More informationxcelligence Cardio Symposium 2014 Cardiotoxicity, QT Prolongation, and Arrhythmia Prediction Using icell Cardiomyocytes: Past, Present, and Future
xcelligence Cardio Symposium 2014 Cardiotoxicity, QT Prolongation, and Arrhythmia Prediction Using icell Cardiomyocytes: Past, Present, and Future Blake Anson Ph.D. Oct 18, 2014 Outline Proarrhythmia Testing
More informationChapter 12: Cardiovascular Physiology System Overview
Chapter 12: Cardiovascular Physiology System Overview Components of the cardiovascular system: Heart Vascular system Blood Figure 12-1 Plasma includes water, ions, proteins, nutrients, hormones, wastes,
More informationPluricyte Cardiomyocytes. Axion BioSystems Maestro TM MEA system
Pluricyte Cardiomyocytes Axion BioSystems Maestro TM MEA system User Guide Version 3.0 / March 2018 Contents 1. Introduction 2 2. Workflow 3 3. Important recommendations 4 4. Equipment, Materials and
More informationSurvivorship: Managing Cardiac Toxicities
Survivorship: Managing Cardiac Toxicities Anecita Fadol, PhD, RN, FNP-BC, FAANP The University of Texas MD Anderson Cancer Center Learning Objectives Identify the causes of cardiac toxicity in cancer survivors
More informationPreparing for Changing Cardiac Safety Regulations. Joy Olbertz, PharmD, PhD
Preparing for Changing Cardiac Safety Regulations Joy Olbertz, PharmD, PhD Questions? Do I still have to assess proarrhythmic potential of my compound in a Thorough QT (TQT) study? If I have a TQT to conduct,
More informationInternational Graduate Research Programme in Cardiovascular Science
1 International Graduate Research Programme in Cardiovascular Science This work has been supported by the European Community s Sixth Framework Programme under grant agreement n LSHM-CT-2005-01883 EUGeneHeart.
More informationMultiparameter In Vitro Assessment of Compound Effects on Cardiomyocyte Physiology Using ipsc Cells
457590JBXXXX10.1177/1087057112457590Jo urnal of Biomolecular ScreeningSirenko et al. 2012 Multiparameter In Vitro Assessment of Compound Effects on Cardiomyocyte Physiology Using ipsc Cells Journal of
More informationRational Approach to Improving Cardiac Arrhythmia Therapy. Rational Approach to Improving Cardiac Arrhythmia Therapy
Rational Approach to Improving Cardiac Arrhythmia Therapy Rational Approach to Improving Cardiac Arrhythmia Therapy Stanley Nattel, MD Stanley Nattel, MD DEDICATED TO THE MASTER OF RATIONAL THERAPEUTICS
More informationMechanisms of Arrhythmogenesis: Focus on Long QT Syndrome (LQTS)
Mechanisms of Arrhythmogenesis: Focus on Long QT Syndrome (LQTS) Craig T. January, MD, PhD Division of Cardiovascular Medicine University of Wisconsin-Madison CSRC-HESI-FDA Rechanneling the Current Cardiac
More informationACRIN Gynecologic Committee
ACRIN Gynecologic Committee Fall Meeting 2010 ACRIN Abdominal Committee Biomarkers & Endpoints in Ovarian Cancer Trials Robert L. Coleman, MD Professor and Vice Chair, Clinical Research Department of Gynecologic
More informationGuidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients
Guidelines on Chemotherapy-induced Nausea Vomiting in Pediatric Cancer Patients COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For
More informationTCP Transl Clin Pharmacol
TCP 2018;26(4):145-149 https://doi.org/10.12793/tcp.2018.26.4.145 Five years of the CiPA project (2013 2018) - what did we learn? Dong-Seok Yim* Department of Clinical Pharmacology and Therapeutics, Seoul
More informationHuman induced pluripotent stem cell derived cardiomyocytes are a more relevant model for assessing drug-induced effects on mitochondrial function
Human induced pluripotent stem cell derived cardiomyocytes are a more relevant model for assessing drug-induced effects on mitochondrial function than H9C2 cells 16 January 2013 SLAS2013 Presentation Outline
More informationMr. Eknath Kole M.S. Pharm (NIPER Mohali)
M.S. Pharm (NIPER Mohali) Drug Class Actions Therapeutic Uses Pharmacokinetics Adverse Effects Other Quinidine IA -Binds to open and inactivated Na+ -Decreases the slope of Phase 4 spontaneous depolarization
More informationDevelopment and Use of Quantitative Adverse Outcome Pathways: Lessons Learned from Application to Cardiotoxicity
Development and Use of Quantitative Adverse Outcome Pathways: Lessons Learned from Application to Cardiotoxicity Chemicals Concentration 0.1 µm 1 µm 10 µm 100 µm Weihsueh A. Chiu, PhD Department of Veterinary
More informationc Ischemia (30 min) Reperfusion (8 w) Supplementary Figure bp 300 bp Ischemia (30 min) Reperfusion (4 h) Dox 20 mg/kg i.p.
a Marker Ripk3 +/ 5 bp 3 bp b Ischemia (3 min) Reperfusion (4 h) d 2 mg/kg i.p. 1 w 5 w Sacrifice for IF size A subset for echocardiography and morphological analysis c Ischemia (3 min) Reperfusion (8
More informationPHARMACOLOGY OF ARRHYTHMIAS
PHARMACOLOGY OF ARRHYTHMIAS Course: Integrated Therapeutics 1 Lecturer: Dr. E. Konorev Date: November 27, 2012 Materials on: Exam #5 Required reading: Katzung, Chapter 14 1 CARDIAC ARRHYTHMIAS Abnormalities
More informationCollin County Community College
Collin County Community College BIOL. 2402 Anatomy & Physiology WEEK 5 The Heart 1 The Heart Beat and the EKG 2 1 The Heart Beat and the EKG P-wave = Atrial depolarization QRS-wave = Ventricular depolarization
More informationNature Neuroscience: doi: /nn Supplementary Figure 1
Supplementary Figure 1 EGFR inhibition activates signaling pathways (a-b) EGFR inhibition activates signaling pathways (a) U251EGFR cells were treated with erlotinib (1µM) for the indicated times followed
More informationCardiotoxicity of molecular. Hovav Nechushtan Hadassah Ein Kerem
Cardiotoxicity of molecular targeting ti agents Hovav Nechushtan Hadassah Ein Kerem Cardiac toxicity Markers and imaging to identify early cardiac dysfunction are outside the scope of this lecture Interesting
More informationPreclinical Approaches to Assess Potential Small Molecule Kinase Inhibitor-Induced Cardiac Toxicity: Past, Present, and Future
Preclinical Approaches to Assess Potential Small Molecule Kinase Inhibitor-Induced Cardiac Toxicity: Past, Present, and Future Baichun Yang, MD, PhD, DABT FDA/CDER/OND/DCRP Opinions presented here are
More informationA 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper)
A 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper) Approved Kinase Inhibitors September 2014 Sponsored by PamGene www.pamgene.com The Kinase Activity Profiling
More informationTargeting the late sodium channel: A new antiarrhythmic paradigm?
Targeting the late sodium channel: A new antiarrhythmic paradigm? Wojciech Zareba, MD, PhD Professor of Medicine/Cardiology University of Rochester Medical Center Rochester, NY Disclosures: - Gilead Sciences:
More informationArrhythmias. Simple-dysfunction cause abnormalities in impulse formation and conduction in the myocardium.
Arrhythmias Simple-dysfunction cause abnormalities in impulse formation and conduction in the myocardium. However, in clinic it present as a complex family of disorders that show variety of symptoms, for
More informationCardiac arrhythmias. Janusz Witowski. Department of Pathophysiology Poznan University of Medical Sciences. J. Witowski
Cardiac arrhythmias Janusz Witowski Department of Pathophysiology Poznan University of Medical Sciences A 68-year old man presents to the emergency department late one evening complaining of increasing
More informationDo we have to change our anti-cancer strategy in case of cardiac toxicity? Guy Jerusalem, MD, PhD
Do we have to change our anti-cancer strategy in case of cardiac toxicity? Point of view of the oncologist Guy Jerusalem, MD, PhD CHU Sart Tilman Liège Anticancer therapy: cardiac toxicity New anticancer
More informationCardiotoxicity from Chemotherapy : From Early Predictors to Therapeutics
Cardiotoxicity from Chemotherapy : From Early Predictors to Therapeutics Richard Sheppard MD FRCPC Director of Heart Failure Research Heart Function Clinic Jewish General hospital Objectives 1. Discuss
More informationLecture outline. Electrical properties of the heart. Automaticity. Excitability. Refractoriness. The ABCs of ECGs Back to Basics Part I
Lecture outline The ABCs of ECGs Back to Basics Part I Meg Sleeper VMD, DACVIM (cardiology) University of Florida Veterinary School Electrical properties of the heart Action potentials Normal intracardiac
More informationCancer survivors. Half of Cancer Survivors Die of Other Conditions. Cause of Death in Cancer Survivors
Cardiotoxicity of Cancer Therapies: Pathogenesis, Diagnosis, and Management Edward T.H. Yeh, M.D. Cancer survivors Now nearly 12 million cancer survivors in U.S. according to NCI 15% were diagnosed 2+
More informationInterpreting Electrocardiograms (ECG) Physiology Name: Per:
Interpreting Electrocardiograms (ECG) Physiology Name: Per: Introduction The heart has its own system in place to create nerve impulses and does not actually require the brain to make it beat. This electrical
More informationUpdate in Cardio-Oncology
Update in Cardio-Oncology Dr. Alexander Lyon BHF Senior Lecturer and Consultant Cardiologist Clinical Lead in Cardio-Oncology Royal Brompton Hospital, London UK President of British Cardio-Oncology Society
More informationCardio-oncology: Basics and Knowing When You Need an Echo
Cardio-oncology: Basics and Knowing When You Need an Echo Vera H. Rigolin, MD, FASE, FACC, FAHA Professor of Medicine Northwestern University Feinberg School of Medicine Medical Director, Echocardiography
More informationBlocking the Late Sodium Current
Non-classical Targets in Antiarrhythmic Therapy Blocking the Late Sodium Current Luiz Belardinelli, MD SVP, Cardiovascular Therapeutics Gilead Sciences, CA, USA Madrid June 28, 2011 Disclosures: Full time
More informationQT prolongation and drug-drug interactions. Filip Josephson M.D., Ph.D Clinical Assessor Swedish Medical Products Agency
QT prolongation and drug-drug interactions Filip Josephson M.D., Ph.D Clinical Assessor Swedish Medical Products Agency Disposition Introduction to QT prolongation Three relevant DDI scenarios Concluding
More informationCancer is diagnosed in > children and adolescents in
AHA Scientific Statement Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research
More informationCardiotoxicity: The View of the Cardiologist
Cardiotoxicity: The View of the Cardiologist Dr. Yael Peled, Cardio-Oncology Interactions: 1.Cardiotoxicity following chemotherapy 2. Co existence of cancer and CVD Aging & common risk factors cardiac
More informationHHS Public Access Author manuscript Circ Res. Author manuscript; available in PMC 2016 June 05.
Tissue and Animal Models of Sudden Cardiac Death Karim Sallam, MD *,1,2,3, Yingxin Li, PhD *,1,2,3, Philip T. Sager, MD 1,2, Steven R. Houser, PhD 4, and Joseph C. Wu, MD, PhD 1,2,3 1 Stanford Cardiovascular
More informationThe pill-in-the-pocket strategy for paroxysmal atrial fibrillation
The pill-in-the-pocket strategy for paroxysmal atrial fibrillation KONSTANTINOS P. LETSAS, MD, FEHRA LABORATORY OF CARDIAC ELECTROPHYSIOLOGY EVANGELISMOS GENERAL HOSPITAL OF ATHENS ARRHYTHMIAS UPDATE,
More informationComparison of Electrophysiological Data From Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes to Functional Preclinical Safety Assays
toxicological sciences 134(2), 412 426 2013 doi:10.1093/toxsci/kft113 Advance Access publication May 20, 2013 Comparison of Electrophysiological Data From Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes
More informationModeling of Anatomy, Electrophysiology and Tension Development in the Human Heart
European Functional Cardiac Modeling Meeting Modeling of Anatomy, Electrophysiology and Tension Development in the Human Heart Dr.-Ing. Gunnar Seemann Overview Electrophysiology Tension development Anatomy
More informationMulti-modal fluorescence imaging of contracting intact hearts
Multi-modal fluorescence imaging of contracting intact hearts ESR4: Vineesh Kappadan Project Supervisor: Prof.Ulrich Parlitz & Dr.Jan Christoph Biomedical Physics Group Max Planck Institute for Dynamics
More informationThe Application of Cell-Based Impedance Technology in Drug Discovery
The Application of Cell-Based Impedance Technology in Drug Discovery Yama A. Abassi, PhD Sr. Director Cell Biology and Assay Development ACEA Biosciences ACEA Biosciences Founded in early Located in San
More informationPluricyte Cardiomyocytes. using the Multiwell MEA System from Multi Channel Systems
Pluricyte Cardiomyocytes using the Multiwell MEA System from Multi Channel Systems User Guide Version 3.1 / March 2018 Contents 1. Introduction 2 2. Workflow 3 3. Important Recommendations 4 4. Equipment,
More informationShock-induced termination of cardiac arrhythmias
Shock-induced termination of cardiac arrhythmias Group members: Baltazar Chavez-Diaz, Chen Jiang, Sarah Schwenck, Weide Wang, and Jinglei Zhang Cardiac arrhythmias, also known as irregular heartbeat, occur
More informationThe mechanism of the cardiac arrhythmias Norbert Jost, PhD
The mechanism of the cardiac arrhythmias Norbert Jost, PhD Department of Pharmacology & Pharmacotherapy, University of Szeged Division for Cardiovascular Pharmacology, Hungarian Academy of Sciences Szeged,
More informationIon channel dysfunction and diseases of the heart
Basisvorlesung (BVO) Zelluläre Signaltransduktion- Krankheitsbilder Sommersemester 2015 902.384 PhD- Programm Molecular Signal Transduction Ion channel dysfunction and diseases of the heart H. Todt Dpt.
More informationChapter 14. Agents used in Cardiac Arrhythmias
Chapter 14 Agents used in Cardiac Arrhythmias Cardiac arrhythmia Approximately 50% of post-myocardial infarction fatalities result from ventricular tachycarida (VT) or ventricular fibrillation (VF). These
More informationDeclaration of conflict of interest
Declaration of conflict of interest State of the Art: Addressing Cardiotoxicity Thomas Force, M.D. Center for Translational Medicine Cardiology Division Temple University School of Medicine Philadelphia
More informationDesign and Analysis of QT/QTc Studies Conceptional and Methodical Considerations Based on Experience
Design and Analysis of QT/QTc Studies Conceptional and Methodical Considerations Based on Experience Dr. Manfred Wargenau, Institute, Düsseldorf OVERVIEW Clinical background The ICH E14 guideline / review
More information